UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients < 65 years with poor prognosis histologically aggressive NHL

Linch, DC; Yung, L; Smith, P; Maclennan, K; Jack, A; Hancock, B; Cunningham, D; ... Trneny, M; + view all (2010) Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients < 65 years with poor prognosis histologically aggressive NHL. BRIT J HAEMATOL , 149 (2) 237 - 243. 10.1111/j.1365-2141.2010.08081.x.

Full text not available from this repository.

Abstract

P>This trial involved 457 patients and sought to assess the value of early intensification with autologous transplantation in patients with poor prognosis histologically aggressive non-Hodgkin lymphoma (NHL) showing a response to initial CHOP (cyclosphosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. Randomization was made at the time of diagnosis with 223 assigned to continuing CHOP and 234 to 3 cycles of CHOP followed by a BEAM (carmustine, etoposide, cytarabine, melphalan) autograft. Analysis was on an intention to treat basis. After the initial three cycles of CHOP 19% of the whole group were in complete response (CR) and 53% in partial remission (PR). At the end of treatment 86% of patients in the CHOP arm had responded with 58% in CR. In the high-dose therapy arm the overall response rate was 83% with 64% in CR (difference between arms not significant). The progression-free survival (PFS) and overall survival at 5 years for the continuing CHOP arm were 38% and 50% respectively, and for the autograft arm were 44% and 50% (differences not significant). Of the patients who attained CR and subsequently relapsed, there were no long-term survivors in the autograft recipients compared to 46% of the continuing CHOP recipients (P = 0 center dot 0008). In conclusion, no survival benefit was demonstrated for an early autograft in first response.

Type: Article
Title: Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients < 65 years with poor prognosis histologically aggressive NHL
DOI: 10.1111/j.1365-2141.2010.08081.x
Keywords: non-Hodgkin Lymphoma, high grade NHL, poor prognosis, autologous transplantation, NON-HODGKINS-LYMPHOMA, BONE-MARROW-TRANSPLANTATION, HIGH-DOSE CHEMOTHERAPY, B-CELL LYMPHOMA, RANDOMIZED CONTROLLED-TRIAL, DETUDE-DES-LYMPHOMES, ELDERLY-PATIENTS, SEQUENTIAL CHEMOTHERAPY, INTERMEDIATE-GRADE, INITIAL TREATMENT
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI: http://discovery.ucl.ac.uk/id/eprint/1308202
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item